Aptorum Group is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutic and diagnostic products. Founded in 2017 and headquartered in Hong Kong, the company focuses on advancing precision medicines across a range of therapeutic areas, including liver disease, infectious disease, cystic fibrosis and neurological disorders. Aptorum Group maintains research and development operations in Asia, Europe and the United States, leveraging collaborations with leading academic institutions and contract research organizations to accelerate its pipeline.
The company’s pipeline is organized into several proprietary platforms. Its MucoRx™ program designs inhaled and locally delivered treatments for respiratory and gastrointestinal conditions, with lead candidates targeting cystic fibrosis and inflammatory bowel diseases. The Infectious Disease platform is developing novel broad-spectrum antibiotics to address emerging drug resistance. In parallel, Aptorum Group’s OrphaRx™ and NeuroRx™ initiatives focus on orphan indications and central nervous system disorders, with early-stage candidates aiming to deliver differentiated mechanisms of action for hard-to-treat diseases.
Aptorum Group conducts clinical trials and preclinical studies across multiple geographies. Its flagship programs have entered Phase 1 and Phase 2 clinical stages in the United States, while preclinical research continues in Hong Kong and Europe. The company employs a translational research model, integrating biomarker discovery, pharmacokinetic profiling and patient stratification to enhance trial success rates. Strategic partnerships with regional hospitals and academic centers provide access to patient populations and specialized expertise in regulatory compliance.
Under the leadership of Chief Executive Officer Henry Fung, M.D., a physician-scientist with extensive drug development experience, Aptorum Group is supported by a management team drawn from leading pharmaceutical and biotechnology firms. The board of directors and scientific advisory committee include experts in clinical medicine, drug safety, regulatory affairs and commercial strategy. Together, the team aims to advance the company’s pipeline toward proof-of-concept milestones and position its assets for potential collaborations or licensing opportunities.
AI Generated. May Contain Errors.
